scholarly journals Serum Levels of BDNF in Patients with Adenoma and Colorectal Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Zhe Wang ◽  
Shuang Wang ◽  
Yu Liu ◽  
Shan Gao ◽  
Yunqing Yu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Diagnostic Performance ◽  
Serum Levels ◽  
Tnm Staging ◽  
Laboratory Method ◽  
Healthy Controls ◽  
Tumor Differentiation ◽  
Combined Detection ◽  
Control Study ◽  
Serum Bdnf

The present study is aimed at examining the serum levels of brain-derived neurotrophic factor (BDNF) and investigating its role in differential diagnosis of colorectal cancer (CRC). Materials and Methods. In a Chinese population, we conducted a case-control study to compare the diagnostic performance of serum levels of BDNF and carcinoembryonic antigen (CEA) for CRC. We enrolled 61 healthy controls, 31 patients with adenomas, and 81 patients with CRC. We explored the correlation between serum levels of BDNF and several pathological features, such as tumor differentiation and TNM staging. Results. The serum levels of BDNF were significantly ( p < 0.0001 ) higher in patients with CRC ( 10.64 ± 3.84 , n = 81 ) than in the healthy controls ( 4.69 ± 1.69   ng / mL , n = 61 ). Serum BDNF also correlated with tumor size, tumor differentiation, and TNM staging ( p < 0.05 ). For early diagnosis, the combination of BDNF (AUC 0.719; 95% CI, 0.621–0.816) and CEA (AUC 0.733; 95% CI, 0.632–0.909) slightly improved the diagnostic performance for CRC (AUC 0.823; 95% CI, 0.737-0.909). Conclusions. Combined detection of serum BDNF and CEA may thus have the potential to become a new laboratory method for the early clinical diagnosis of CRC.

Exploring The Clinical Significance of Serum Angiopoietin-2 In Breast Cancer Patients

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Abeer I Abd Elmagid ◽  
Hala Abdel Al ◽  
Wessam El Sayed Saad ◽  
Seham Kamal Mohamed
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Tnm Staging ◽  
Control Group ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Female Patients ◽  
Significant Difference ◽  
Angiopoietin 2

Abstract Background Breast cancer is the most common cancer among women and one of the most important causes of death among them.Angiogenesis is an important step for primary tumor growth, invasiveness, and metastases. Angiopoietins are well-recognized endothelial growth factors that are involved in angiogenesis associated with tumors. Aim To explore the diagnostic significance of serum angiopoietin-2 (Ang-2) in breast cancer and to evaluate its prognostic efficacy through studying the degree of its association with the TNM staging of the disease. Patients and Methods This study was conducted on (35) Egyptian female patients who were diagnosed as breast cancer according to histopathological examination of breast biopsy (Group 1, Breast Cancer Patients) and (25) female patients with benign breast diseases (Group II, Pathological Control Patients), in addition to (20) age - matched apparently healthy, free mammogram, females serving as healthy controls (Group III, Healthy Controls). For all participants, measurement of serum Ang-2 was done using enzyme linked immunosorbent assay (ELISA) technique. Results A highly significant increased levels of Ang-2 was observed in breast cancer patients when compared to healthy control group (Z = 4.95, p &lt; 0.01). However, no significant difference was observed in Ang-2 levels between breast cancer patients group and pathological control group (Z = 3.37, p &gt; 0.05). No significant difference was detected in Ang-2 levels in relation to TNM stage and histological grade. No significant correlation was found between Ang-2 levels and serum levels of CA15-3, hormone receptors, HER2/new receptor status (p &gt; 0.05, respectively). Conclusion This study revealed that Ang-2 serum levels were significantly increased in patient with breast cancer compared with healthy controls, indicating that high Ang-2 level is a promising non invasive biomarker for breast cancer diagnosis. However, no significant difference of Ang-2 levels was detected in relation of breast TNM staging in the population studied.

Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9070-9070 ◽  
Author(s):  
J. L. Vardy ◽  
C. Booth ◽  
G. R. Pond ◽  
H. Zhang ◽  
J. Galica ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Cognitive Function ◽  
Healthy Volunteers ◽  
Cognitive Dysfunction ◽  
Serum Levels ◽  
Healthy Controls ◽  
Post Surgery ◽  
Cytokine Levels ◽  
Perceived Cognitive Function

9070 Background: Cytokines have been associated with fatigue and cognitive dysfunction. Here we evaluated plasma cytokine levels in pts with colorectal cancer (CRC) and breast cancer (BC) who were free of evident disease, and in healthy volunteers. Methods: Serum levels of 10 cytokines were measured using a LiquiChip assay on 251 subjects. CRC pts (n=136, ages 23–75) were evaluated at baseline (mean 8 weeks post-surgery [n=107] or before surgery [n=29]), with repeat measures at 6 months (56 post chemotherapy [CT], 14 without CT) and 12 months (32 post CT, 7 without CT). BC pts (n=51, ages 29–60) were within 5 years of diagnosis (33 after adjuvant CT). Healthy volunteers (n=64) had ages 20–62. Cancer pts completed questionnaires for fatigue & QOL (FACT-F), anxiety/depression (GHQ), and perceived cognitive function (FACT-COG); they had neuropsychological assessment. Results: Cytokines were elevated in all cancer groups compared to healthy controls (p-values <0.001; selected data in table ). Values were highest after surgery but remained significantly higher than healthy controls at 6–60 months after diagnosis, with a trend to being higher in cancer patients who had not received CT. There was a trend to elevated cytokines being associated with greater fatigue and cognitive impairment in both CRC and BC, but no association with QOL or anxiety & depression. Conclusions: Cytokine levels were elevated in all cancer groups compared to healthy volunteers and remained elevated up to 5 years post diagnosis; they may be associated with cognitive dysfunction and fatigue. [Table: see text] No significant financial relationships to disclose.

Serum levels of TIMP-1 and MMP-7 as potential biomarkers in patients with metastatic colorectal cancer

2019 ◽  
Vol 34 (3) ◽  
pp. 292-301 ◽  
Author(s):  
Michal Vočka ◽  
Daniel Langer ◽  
Vladimir Fryba ◽  
Jaromir Petrtyl ◽  
Tomas Hanus ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Serum Levels ◽  
Healthy Controls ◽  
Serum Samples ◽  
Gastrointestinal Malignancies ◽  
Matrix Metalloproteinase 7 ◽  
Growth Promoting ◽  
Potent Growth

Objective: Tissue inhibitor of metalloproteinases 1 (TIMP-1) and matrix metalloproteinase 7 (MMP-7) were reported to have potent growth promoting activity. Lack of balance between MMPs and TIMPs is an important factor in the development of gastrointestinal malignancies. Methods: We collected serum samples from 97 patients with metastatic colorectal cancer and 79 samples from healthy controls. Serum levels of TIMP-1 and MMP-7 were measured immunochemically and compared with standard tumor markers carcinoembryonic antigen and CA19-9. Results: Serum levels of TIMP-1 and MMP-7 were significantly higher in patients with colorectal cancer compared to healthy controls (both, P < 0.001). TIMP-1 and MMP-7 correlate with the presence of colon involvement (P = 0.001; P = 0.012) and the presence of liver metastases (P = 0.002; P = 0.037), and negatively correlate with pulmonary metastases (P = 0.014; P = 0.005). MMP-7 had similar sensitivity and the same specificity as carcinoembryonic antigen. TIMP-1 and MMP-7 had better sensitivity than CA19-9. TIMP-1 and MMP-7 level correlate with worse outcome (P = 0.002). Conclusion: The results indicate that TIMP-1 and MMP-7 are effective biomarkers in patients with metastatic colorectal cancer with good sensitivity. TIMP-1 and MMP-7 levels strongly correlate with the extent of liver disease and have prognostic value.

scholarly journals Relationship between Levels of Brain-Derived Neurotrophic Factor and Metabolic Parameters in Patients with Type 2 Diabetes Mellitus

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Banu Boyuk ◽  
Serife Degirmencioglu ◽  
Hande Atalay ◽  
Savas Guzel ◽  
Ayse Acar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Metabolism ◽  
Neurotrophic Factor ◽  
Serum Levels ◽  
Healthy Controls ◽  
Glucose And Lipid Metabolism ◽  
Serum Bdnf

Background and Aim. Studies have suggested that brain-derived neurotrophic factor (BDNF) plays a role in glucose and lipid metabolism and inflammation. The aim of this study was to evaluate the relationship between serum BDNF levels and various metabolic parameters and inflammatory markers in patients with type 2 diabetes mellitus (T2DM).Materials and Methods. The study included 88 T2DM patients and 33 healthy controls. Fasting blood samples were obtained from the patients and the control group. The serum levels of BDNF were measured with an ELISA kit. The current paper introduces a receiver-operating characteristic (ROC) generalization curve to identify cut-off for the BDNF values in type 2 diabetes patients.Results. The serum levels of BDNF were significantly higher in T2DM patients than in the healthy controls (206.81 ± 107.32 pg/mL versus 130.84 ± 59.81 pg/mL;P<0.001). They showed a positive correlation with the homeostasis model assessment of insulin resistance (HOMA-IR) (r=0.28;P<0.05), the triglyceride level (r=0.265;P<0.05), and white blood cell (WBC) count (r=0.35;P<0.001). In logistic regression analysis, age (P<0.05), body mass index (BMI) (P<0.05), C-reactive protein (CRP) (P<0.05), and BDNF (P<0.01) were independently associated with T2DM. In ROC curve analysis, BDNF cut-off was 137.Conclusion. The serum BDNF level was higher in patients with T2DM. The BDNF had a cut-off value of 137. The findings suggest that BDNF may contribute to glucose and lipid metabolism and inflammation.

scholarly journals Rather than Rs1800796 Polymorphism, Expression of Interleukin-6 Is Associated with Disease Progression of Chronic HBV Infection in a Chinese Han Population

2013 ◽  
Vol 35 ◽  
pp. 799-805 ◽  
Author(s):  
Shengli Tang ◽  
Zhisu Liu ◽  
Yongxi Zhang ◽  
Yueming He ◽  
Dingyu Pan ◽  
...  
Keyword(s):  
Disease Progression ◽  
Interleukin 6 ◽  
Staging System ◽  
Serum Levels ◽  
Hbv Infection ◽  
Healthy Controls ◽  
Chinese Han ◽  
Chronic Hbv Infection ◽  
Chronic Hbv ◽  
Control Study

Interleukin-6 plays an important role in chronic inflammation as well as tumor growth and progression. Here, a case-control study was undertaken to investigate the association of rs1800796 polymorphism of IL-6 gene and serum levels with disease progression of chronic HBV infection. Rs1800796 polymorphism was genotyped in 641 Chinese Han patients with chronic HBV infection, including 23 IT, 25 IC, 292 CHB, 153 LC, and 148 HCC patients and 265 healthy controls. Serum IL-6 levels were measured in 23 IT, 25 IC, 47 CHB, 41 LC, and 49 HCC patients and 45 healthy controls, and the classifications of HCC were accorded to BCLC staging system. We found no significant association between rs1800796 polymorphism and disease progression of chronic HBV infection; however, serum IL-6 levels showed significant statistical differences between patients with CHB, LC, and HCC. Moreover, statistical differences can be observed in patients with terminal stage HCC compared with those of early to intermediate or advanced stage HCC. Our findings suggest that rs1800796 polymorphism unlikely contribute significantly to affect the progression of chronic HBV infection, and serum IL-6 levels can act as a useful indicator for disease progression and severity of chronic HBV infection.

scholarly journals Serum interleukin-30 level in patients with psoriasis and its correlation with psoriasis severity: a case-control study

2021 ◽  
Vol 49 (4) ◽  
pp. 030006052110040
Author(s):  
Nergez Sabah Omar ◽  
Xinxin Long ◽  
Jiayi Xian ◽  
Henok Kessete Afewerky ◽  
Saeed Ghulam Hussain ◽  
...  
Keyword(s):  
Statistical Analysis ◽  
Immunosorbent Assay ◽  
Case Control Study ◽  
Severity Index ◽  
Serum Levels ◽  
Case Control ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Psoriasis Severity ◽  
Control Study

Objectives To examine the serum levels of interleukin (IL)-30 in patients with psoriasis and evaluate the correlations with the Psoriasis Area and Severity Index (PASI). Methods Serum was collected from 26 patients with psoriasis and 26 healthy controls in a case–control setting, and the level of IL-30 was determined using an enzyme-linked immunosorbent assay. Statistical analysis of the IL-30 levels among groups and further correlation analyses of IL-30 levels with PASI scores were performed. Results A significant increase in the level of IL-30 in patients with psoriasis compared with healthy controls was observed. In addition, a positive correlation between the IL-30 concentration and PASI scores was found in patients with psoriasis. Conclusion IL-30 is presumably involved in the proliferation of epidermal cells during the development of psoriasis. Further studies with a larger number of participants are required to comprehensively elucidate the biological roles of IL-30 in the pathogenesis of psoriasis.

scholarly journals Metabolomic Profiling Identified Serum Metabolite Biomarkers and Related Metabolic Pathways of Colorectal Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Chengjian Zhang ◽  
Shengnan Zhou ◽  
Huijing Chang ◽  
Feng Zhuang ◽  
Yang Shi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metabolic Pathways ◽  
Roc Curves ◽  
Serum Levels ◽  
Serum Biomarkers ◽  
Healthy Controls ◽  
Dodecylbenzenesulfonic Acid ◽  
Metabolomic Profiling ◽  
Liquid Chromatography Tandem Mass ◽  
Healthy Control

Background. The screening and early detection of colorectal cancer (CRC) still remain a challenge due to the lack of reliable and effective serum biomarkers. Thus, this study is aimed at identifying serum biomarkers of CRC that could be used to distinguish CRC from healthy controls. Methods. A prospective 1 : 2 individual matching case-control study was performed which included 50 healthy control subjects and 98 CRC patients. Untargeted metabolomic profiling was conducted with liquid chromatography tandem mass spectrometry (LC-MS/MS) to identify CRC-related metabolites and metabolic pathways. Results. In total, 178 metabolites were detected, and an orthogonal partial least-squares-discriminant analysis (OPLS-DA) model was useful to distinguish CRC patients from healthy controls. Nine metabolites showed significantly differential serum levels in CRC patients under the conditions of variable importance in projection VIP > 1 , p < 0.05 using Student’s t -test, and fold change FC ≥ 1.2 or ≤0.5. The above nine metabolites were 3-hydroxybutyric acid, hexadecanedioic acid, succinic acid semialdehyde, 4-dodecylbenzenesulfonic acid, prostaglandin B2, 2-pyrocatechuic acid, xanthoxylin, 12-hydroxydodecanoic acid, and formylanthranilic acid. Four potential biomarkers were identified to diagnose CRC through ROC curves: hexadecanedioic acid, 4-dodecylbenzenesulfonic acid, 2-pyrocatechuic acid, and formylanthranilic acid. All AUC values of these four serum biomarkers were above 0.70. In addition, the exploratory analysis of metabolic pathways revealed the activated states for the vitamin B metabolic pathway and the alanine, aspartate, and glutamate metabolic pathways associated with CRC. Conclusion. The 4 identified potential metabolic biomarkers could discriminate CRC patients from healthy controls, and the 2 metabolic pathways may be activated in the CRC tissues.

scholarly journals High expression of FABP4 and FABP6 in patients with colorectal cancer

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Yaqin Zhang ◽  
Xiaotong Zhao ◽  
Lili Deng ◽  
Xueting Li ◽  
Ganbiao Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Western Blot ◽  
Odds Ratio ◽  
Adjusted Odds Ratio ◽  
Serum Levels ◽  
Colorectal Tumor ◽  
Tumor Tissues ◽  
Protein Expressions ◽  
Combined Detection

Abstract Objective To explore the relationship between FABP4 and FABP6 expression and the pathogenesis of colorectal cancer (CRC) and their potential as biomarkers in the diagnosis of CRC. Methods In total, 100 CRC patients and 100 controls were enrolled. The serum levels of FABP4 and FABP6 were detected by enzyme-linked immunosorbent assay (ELISA) before and 2 weeks after radical resection of CRC. The protein expressions of FABP4 and FABP6 were observed in colorectal tumor tissues and adjacent tissues by immunohistochemistry and western blot, respectively. The diagnostic performance of FABP4 and FABP6 in patients with CRC was evaluated by receiver operating characteristic (ROC) curve analysis. Results The serum levels of FABP4 and FABP6 in patients with CRC were higher than the levels in the controls before surgery (P < 0.001), and significantly decreased at 2 weeks after operation (P < 0.001). Immunohistochemistry showed that FABP4 and FABP6 were mainly distributed in the cytoplasm of human colorectal tumor tissues, and only a small amount distributed in adjacent tissues. Western blot revealed that the protein expressions of FABP4 and FABP6 were significantly higher in tumor tissues than in adjacent tissues (P < 0.001, P = 0.002, respectively). Tumors with high and low FABP4 and FABP6 expression have no significant correlation in tumor size, tumor site, distant organ and lymph node metastasis, histologic grade, lymphatic permeation, neurological invasion, vascular invasion, and Duke’s and TNM classification. Multivariate logistic regression analysis showed that FABP4 and FABP6 were independent risk factors for CRC (adjusted odds ratio 1.916; 95%CI 1.340–2.492; P < 0.001; adjusted odds ratio 2.162; 95%CI 1.046, 1.078); P < 0.001, respectively). In discriminating CRC from the normal control, the optimal sensitivity of FABP4 and FABP6 were 93.20% (95%CI 87.8–96.7) and 83.70% (95%CI 76.7–89.3), respectively, while the optimal specificity of FABP4 and FABP6 were 48.8% (95%CI 39.8–57.9) and 58.4% (95%CI 49.2–67.1), respectively. When combined detection of serum carcinoembryonic (CEA) and FABP4 and FABP6, the optimal sensitivity and specificity were 61.33% (95%CI 53.0–69.2) and 79.82% (95%CI 71.3–86.8), respectively. Conclusion Increased expression of FABP4 and FABP6 not only were strong risk factors for the development of CRC but could also represent a potential biomarker for CRC diagnosis in Chinese patients. Combined detection of CEA with FABP4 and FABP6 could improve the diagnostic efficacy of CRC.

scholarly journals Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer

2021 ◽  
Vol 49 (5) ◽  
pp. 030006052110125
Author(s):  
Xiwen Huang ◽  
Yongquan Lan ◽  
En Li ◽  
Jiaquan Li ◽  
Qiaoting Deng ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Area Under The Curve ◽  
Serum Levels ◽  
Diagnostic Value ◽  
Carbohydrate Antigen ◽  
Tissue Inhibitor Of Metalloproteinase ◽  
Enzyme Linked Immunosorbent Assay ◽  
Detection Model ◽  
Specificity And Sensitivity ◽  
Combined Detection

Objective Colorectal cancer (CRC) is one of the most common and lethal malignancies. The identification of precise and noninvasive biomarkers is urgently needed to aid the early diagnosis and clinical management of CRC. Methods A total of 112 patients with CRC and 115 healthy control subjects were included in this study. Serum levels of matrix metalloproteinase (MMP)-7, MMP-9, MMP-11, tissue inhibitor of metalloproteinase (TIMP)-1, and TIMP-2 were analyzed by enzyme-linked immunosorbent assay, and carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9 levels were measured using an automatic immunoassay analyzer. Results MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 levels were all significantly higher in CRC patients compared with healthy controls. MMP-7, TIMP-1, and CEA levels were also closely related to clinicopathologic features in patients with CRC. The combination of serum CEA, MMP-7, and TIMP-1 significantly improved the diagnostic value compared with any single marker (area under the curve 0.858–0.890). Furthermore, a combined detection model including MMP-7, TIMP-1, and CEA improved both the specificity and sensitivity for detecting CRC. Conclusions The results showed that combined detection of CEA, MMP-7, and TIMP-1 in serum could provide a specific and sensitive biomarker for the diagnosis of CRC.

Sign in / Sign up

Export Citation Format

Share Document